<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="754">
  <stage>Registered</stage>
  <submitdate>16/09/2005</submitdate>
  <approvaldate>23/09/2005</approvaldate>
  <actrnumber>ACTRN12605000493640</actrnumber>
  <trial_identification>
    <studytitle>The Asia Pacific NeuroAIDS Consortium (APNAC) Study</studytitle>
    <scientifictitle>A cross-sectional study of HIV-related Neurological Disorders in Ten Countries of the Asia Pacific Region</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>HIV </healthcondition>
    <healthcondition>HIV-related neurological diseases</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The is a cross-sectional study to determine the prevalence of HIV-related Neurological Disorders in the countries of the Asia-Pacific Region. Researchers will visit each country site for a period of 2-3 weeks and work with local investigators. Outpatients will be evaluated once-only for the presence of HIV-related symptomatic peripheral neuropathy and HIV-related Neurocognitive Impairment. Inpatients at the sites will be evaluated once-only for the presence of HIV dementia, cerebral toxoplasmosis, cerebral tuberculosis, cryptococal meningitis, lymphoma, PML and CMV encephalitis.</interventions>
    <comparator />
    <control />
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>1. To determine the prevalence of HIV-related neurocognitive impairment and ADC at the APNAC-10 sites</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>2. To determine the prevalence of symptomatic peripheral sensory neuropathy at the APNAC-10 sites</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>3. To determine the prevalence of central nervous system opportunistic infections and tumours at the APNAC-10 sites</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the degree of cognitive impairment in patients presenting with HIV-related cognitive impairment at the APNAC-10 sites.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the CD4 cell counts, HIV viral loads HIV viral loads and prior AIDS defining illnesses (ADIs) of patients presenting with HIV-related neurocognitive impairment and ADC at the APNAC-10 sites.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare the prevalence of HIV-related neurocognitive impairment and ADC at the APNAC-10 sites to the published pre-HAART prevalence of these conditions in developed countries.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare the prevalence of HIV-related neurocognitive impairment and ADC between the APNAC-10 sitesTo describe the severity of symptoms of patients presenting with symptomatic peripheral sensory neuropathy at the APNAC-10 sites.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the CD4 cell counts, HIV viral loads HIV viral loads and prior ADIs of patients presenting with symptomatic peripheral sensory neuropathy at the APNAC-10 sites.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine what proportion of symptomatic peripheral sensory neuropathy may be ascribed to HIV alone, to the use of nucleoside analogues.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare the prevalence of symptomatic peripheral sensory neuropathy at the APNAC-10 sites to the published pre-HAART prevalence of these conditions in developed countries.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare the prevalence of symptomatic peripheral sensory neuropathy between the APNAC-10 sites.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the prevalence of asymptomatic peripheral neuropathy.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To describe the presenting symptoms and signs of patients presenting with CNS OIs and tumours at the APNAC-10 sites.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To describe the neuroradiological findings of patients presenting with CNS OIs and tumours at the APNAC-10 sites.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the serological, culture and other diagnostic test results of patients presenting with CNS OIs and tumours at the APNAC-10 sites.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the CD4 cell counts, HIV viral loads and prior ADIs of patients presenting with CNS OIs and tumours at the APNAC-10 sites.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare the prevalence of CNS OIs and tumours at the APNAC-10 sites to the published pre-HAART prevalence of these conditions in developed countries.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare the prevalence of CNS OIs and tumours between the APNAC-10 sites.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients are HIV infected.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Convenience sample</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/07/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>600</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>National Institute of Mental Health and National Institute of Neurological Disorders and Stroke</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Institute of Mental Health</fundingname>
      <fundingaddress />
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Institute of Neurological Disorders and Stroke</fundingname>
      <fundingaddress />
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr. Edwina Wright</name>
      <address>Infectious Diseases Department
The Alfred Hospital
2nd Floor
Burnet Institute
Commercial Road
Melbourne VIC 3004</address>
      <phone>+61 3 92766078</phone>
      <fax>+61 3 92762431</fax>
      <email>e.wright@alfred.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr. Edwina Wright</name>
      <address>Infectious Diseases Department
The Alfred Hospital
2nd Floor
Burnet Institute
Commercial Road
Melbourne VIC 3004</address>
      <phone>+61 3 92766078</phone>
      <fax>+61 3 92762431</fax>
      <email>e.wright@alfred.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>